{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:47:06Z","timestamp":1791920826052,"version":"4.3.4"},"reference-count":67,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The purpose of this review is to critically analyse data regarding the prevalence and risk factors for developing a prolonged QTc interval and subsequent sudden cardiac death (SCD) in persons living with HIV (PLWH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature search using PubMed and Google Scholar databases was performed using the following search terms: \u2018HIV and prolonged QTc\u2019 and \u2018managing HIV-patients with prolonged QTc\u2019. References within articles of interest were also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results\/Discussion<\/jats:title>\n                    <jats:p>\n                      PLWH are at an increased risk of having a prolonged QTc interval. Some risk factors for this include the virus itself, concomitant medications, comorbid conditions, addictions and electrolyte disturbances. PLWH who have an increased HIV RNA viral load or decreased CD4\n                      <jats:sup>+<\/jats:sup>\n                      T-cell count are at further risk for progressing to sudden cardiac death (SCD). Many medications commonly prescribed in the PLWH population, such as antiretrovirals and antimicrobials used in opportunistic infection prophylaxis, have also been shown to promote QTc prolongation through inhibition of human ether-a-go-go potassium channels or through drug metabolism inhibition of other QTc prolonging drugs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Due to the high number of risk factors associated with QTc prolongation, clinicians should incorporate baseline and routine ECG monitoring for PLWH to potentially lower the increased risk of SCD in PLWH.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3851\/imp3335","type":"journal-article","created":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T11:40:47Z","timestamp":1569843647000},"page":"459-465","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["Abnormal QTc Syndrome in HIV-Infected Patients: A Systematic review of Prevalence and Risk Factors"],"prefix":"10.1177","volume":"24","author":[{"given":"Daniel B","family":"Chastain","sequence":"first","affiliation":[{"name":"Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Albany, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P","family":"Veve","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Translational Science, University of Tennessee College of Pharmacy, Knoxville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie L","family":"Wagner","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University of Mississippi School of Pharmacy, Jackson, MS, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,8,1]]},"reference":[{"key":"bibr1-IMP3335","doi-asserted-by":"publisher","DOI":"10.1016\/j.cnur.2017.10.005"},{"key":"bibr2-IMP3335","unstructured":"UNAIDS. Global HIV & AIDS statistics \u2013 2018 fact sheet. (Accessed 30 April 2019.) Available from http:\/\/www.unaids.org\/en\/resources\/fact-sheet"},{"key":"bibr3-IMP3335","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.10657"},{"key":"bibr4-IMP3335","unstructured":"UNAIDS. DATA 2018. (Accessed 30 April 2019.) Available from https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/unaids-data-2018_en.pdf"},{"key":"bibr5-IMP3335","doi-asserted-by":"publisher","DOI":"10.2459\/JCM.0000000000000436"},{"key":"bibr6-IMP3335","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-013-0168-6"},{"key":"bibr7-IMP3335","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-017-1053-9"},{"key":"bibr8-IMP3335","doi-asserted-by":"publisher","DOI":"10.1016\/j.jelectrocard.2010.10.027"},{"key":"bibr9-IMP3335","first-page":"1657","volume":"97","author":"Sani M.U.","year":"2005","journal-title":"J Natl Med Assoc"},{"key":"bibr10-IMP3335","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8159.1997.tb05439.x"},{"key":"bibr11-IMP3335","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12031"},{"key":"bibr12-IMP3335","unstructured":"Freiberg M., Duncan M.S., Kundu S. Sudden cardiac death among HIV-infected and -uninfected veterans.\n                      CROI\n                      . 4\u20137 March 2019; Seattle, WA, USA. Abstract 33"},{"key":"bibr13-IMP3335","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.02.024"},{"key":"bibr14-IMP3335","doi-asserted-by":"publisher","DOI":"10.1111\/anec.12162"},{"key":"bibr15-IMP3335","first-page":"4","volume":"2","author":"Gaharwar R.","year":"2017","journal-title":"Int J Adv Med"},{"key":"bibr16-IMP3335","doi-asserted-by":"publisher","DOI":"10.1007\/BF01845498"},{"key":"bibr17-IMP3335","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000408"},{"key":"bibr18-IMP3335","doi-asserted-by":"publisher","DOI":"10.1159\/000320216"},{"key":"bibr19-IMP3335","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2018-313667"},{"key":"bibr20-IMP3335","doi-asserted-by":"publisher","DOI":"10.1086\/508873"},{"key":"bibr21-IMP3335","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17950-1"},{"key":"bibr22-IMP3335","doi-asserted-by":"publisher","DOI":"10.2174\/1874613601812010181"},{"key":"bibr23-IMP3335","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-010-0053-5"},{"key":"bibr24-IMP3335","volume-title":"Package insert","author":"Sustiva\u00ae.","year":"2016"},{"key":"bibr25-IMP3335","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services. 2019. (Accessed 30 April 2019.) Available from http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf"},{"key":"bibr26-IMP3335","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A454"},{"key":"bibr27-IMP3335","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2006.11.001"},{"key":"bibr28-IMP3335","author":"Boven K.","year":"2009","journal-title":"IDWeek."},{"key":"bibr29-IMP3335","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833032ed"},{"key":"bibr30-IMP3335","doi-asserted-by":"publisher","DOI":"10.1111\/jce.13032"},{"key":"bibr31-IMP3335","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2011.47.1.1583188"},{"key":"bibr32-IMP3335","unstructured":"Center for Drug Evaluation and Research. Rilpivirine EFApfN. 2011. (Accessed 30 April 2019.) Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/202022Orig1s000Approv.pdf"},{"key":"bibr33-IMP3335","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60983-5"},{"key":"bibr34-IMP3335","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60936-7"},{"key":"bibr35-IMP3335","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-015-0087-7"},{"key":"bibr36-IMP3335","doi-asserted-by":"publisher","DOI":"10.1310\/hct1005-328"},{"key":"bibr37-IMP3335","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q422"},{"key":"bibr38-IMP3335","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328341dcc0"},{"key":"bibr39-IMP3335","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011400071"},{"key":"bibr40-IMP3335","volume-title":"Package insert","author":"Kaletra.","year":"2010"},{"key":"bibr41-IMP3335","unstructured":"FDA drug safety communication: ongoing safety review of invirase (saquinavir) and possible association with abnormal heart rhythms 2016. (Accessed 30 April 2019.) Available from https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/fda-drug-safety-communication-ongoing-safety-review-invirase-saquinavir-and-possible-association"},{"key":"bibr42-IMP3335","author":"Reyataz\u00ae.","year":"2018","journal-title":"Package insert"},{"key":"bibr43-IMP3335","doi-asserted-by":"publisher","DOI":"10.2165\/11531850-000000000-00000"},{"key":"bibr44-IMP3335","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2261-12-124"},{"key":"bibr45-IMP3335","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5849(98)00199-3"},{"key":"bibr46-IMP3335","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. 2019. (Accessed 30 April 2019.) Available from http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf"},{"key":"bibr47-IMP3335","doi-asserted-by":"publisher","DOI":"10.1177\/106002809202601104"},{"key":"bibr48-IMP3335","doi-asserted-by":"publisher","DOI":"10.1378\/chest.105.2.389"},{"key":"bibr49-IMP3335","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-199304000-00007"},{"key":"bibr50-IMP3335","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5273(97)02968-9"},{"key":"bibr51-IMP3335","doi-asserted-by":"publisher","DOI":"10.1378\/chest.112.3.646"},{"key":"bibr52-IMP3335","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00658.x"},{"key":"bibr53-IMP3335","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(07)70187-1"},{"key":"bibr54-IMP3335","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02794-13"},{"key":"bibr55-IMP3335","volume-title":"Package insert","author":"Primaquine phosphate.","year":"2017"},{"key":"bibr56-IMP3335","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-010-0517-6"},{"key":"bibr57-IMP3335","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003833"},{"key":"bibr58-IMP3335","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040582"},{"key":"bibr59-IMP3335","unstructured":"FDA drug safety communication: azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms. 2018. (Accessed 30 April 2019.) Available from https:\/\/www.fda.gov\/media\/85787\/download"},{"key":"bibr60-IMP3335","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.09.029"},{"key":"bibr61-IMP3335","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201402-0385CI"},{"key":"bibr62-IMP3335","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(96)00377-4"},{"key":"bibr63-IMP3335","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw591"},{"key":"bibr64-IMP3335","first-page":"11","volume":"2017","author":"Salem M.","year":"2017","journal-title":"Glob Cardiol Sci Pract"},{"key":"bibr65-IMP3335","doi-asserted-by":"publisher","DOI":"10.4061\/2010\/524764"},{"key":"bibr66-IMP3335","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit467"},{"key":"bibr67-IMP3335","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.12.1280"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3335","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3851\/IMP3335","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3335","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:52:48Z","timestamp":1777380768000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP3335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,1]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.3851\/IMP3335"],"URL":"https:\/\/doi.org\/10.3851\/imp3335","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,1]]}}}